Metagenomi Therapeutics Inc
NASDAQ:MGX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
M
|
Metagenomi Therapeutics Inc
NASDAQ:MGX
|
US |
Intrinsic Value
The intrinsic value of Metagenomi Therapeutics Inc (MGX) under the Base Case is 0.7977 USD per share. Compared with the current market price of 0.8056 USD, the stock appears Overvalued by 1% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Metagenomi Therapeutics Does
Metagenomi is a gene-editing company that uses metagenomic data to find new enzymes and CRISPR systems for making genetic medicines. In plain terms, it searches natural DNA from many organisms, pulls out useful gene-editing tools, and turns them into research programs and drug candidates. Its work is aimed at correcting or replacing faulty genes that cause disease.
- Headquarters
- United States of America US
- Employees
- 119
- IPO date
- Feb 9, 2024
Earnings Waterfall
Metagenomi Therapeutics Inc
The intrinsic value for Metagenomi Therapeutics Inc (MGX) under the Base Case is 0.7977 USD.
Compared with the current market price of 0.8056 USD, the stock appears Overvalued by 1% .